OS Therapies Names Bob Langer to Advisory Board, Eyes H2 2026 OST-HER2 BLA and $205M PRV
OS Therapies appointed Dr. Robert S. Langer—cofounder of over 40 biotech companies, including Moderna—to its strategic advisory board to advance its listeria-based oncology pipeline. The company plans a BLA filing for OST-HER2 in osteosarcoma in H2 2026 with ODD, FTD and RPDD designations and a potential $205M PRV sale.
1. Strategic Advisor Appointment
OS Therapies appointed Dr. Robert S. Langer, cofounder of over 40 biotechnology companies including Moderna, to its strategic advisory board. He will guide prioritization of the company’s listeria-based oncology product candidates and oversee selection of tunable Antibody Drug Conjugate (tADC) programs for further development.
2. OST-HER2 Regulatory Pathway
The company is targeting a Biologics License Application (BLA) submission for OST-HER2 in recurrent, fully resected pulmonary metastatic osteosarcoma in the second half of 2026. OST-HER2 holds Orphan Drug, Fast Track and Rare Pediatric Disease designations in the U.S. and Advanced Therapy Medicinal Product status in Europe, making it eligible for a Priority Review Voucher valued at up to $205 million.
3. Pipeline Development and Funding Strategy
Dr. Langer’s expertise in oncology immunotherapies and drug delivery technologies will support combination strategies with other biotech platforms and engagement with international regulators. OS Therapies plans to leverage product revenues, partnership agreements and potential PRV sale proceeds to fund continued expansion of its solid tumor pipeline.